Symptomatic SARS-CoV-2 breakthrough infections broaden the repertoire of Spike-reactive CD4 T cells
mBio · 2026
DOI: 10.1128/mbio.03549-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, 2026. Verfasst von Emil Johansson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, California, USA. Hauptthemen laut MEDLINE: COVID-19, Spike Glycoprotein, Coronavirus, CD4-Positive T-Lymphocytes, SARS-CoV-2. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
SARS-CoV-2 breakthrough infections (BTIs) are relatively common, but little is known in terms of differentiating responses associated with asymptomatic BTI (ABTI) versus symptomatic BTI (SBTI). Here, we investigated the impact of ABTI and SBTI on antibody and T-cell responses toward Spike. SBTI donors had significantly higher plasma anti-Spike RBD IgG titers compared to both ABTI and SARS-CoV-2 vaccinated donors with no signs of previous infection (VAX) donors. While no impact of ABTI or SBTIs was found in the magnitude of Spike-specific CD4 and CD8 T-cell responses, both ABTI and SBTI donors had significantly higher CD4 T-cell responses toward non-Spike antigens. In-depth characterization of Spike-specific CD4 and CD8 T cells at scRNA/TCRseq level revealed that ABTI and SBTI induced different alterations of the CD4 compartment. These included an IFNG high -skewed response among cytokine-producing cells and a concurrent expansion of type II IFN-responsive T H 17-like cells in SBTI. SBTI donors were further found to have an increased CD4 TCR repertoire diversity compared to VAX donors. ABTI-associated alterations of the Spike-specific compartment were intermediate between SBTI and VAX groups, likely reflecting lower antigen exposure and less inflammatory environment during ABTIs versus SBTIs. IMPORTANCE SARS-CoV-2 mRNA vaccines have been shown to induce robust T-cell responses, crucial for long-term protection against severe SARS-CoV-2 infection. Hybrid immunity, created by a combination of vaccination and infection, has been associated with improved protection against severe SARS-CoV-2 infection. Here, we have investigated the impact of asymptomatic and symptomatic breakthrough infections (BTIs) on T-cell responses toward Spike, compared to donors that have only received mRNA SARS-CoV-2 vaccines. Symptomatic, and to a lesser extent asymptomatic, BTIs broadened the repertoire of Spike-reactive CD4 T cells and induced a more pro-inflammatory Spike-reactive T-cell response capable of enhancing activation of TH17-like cells. These findings represent the first characterization of T-cell responses in ABTI in comparison to SBTI, and in comparison to vaccinated individuals (VAX) who did not experience BTIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, California, USA.
- Department of Experimental Medical Science, Lund University, Lund, Sweden.
- Bioinformatics and Systems Biology Graduate Program, University of California, San Diego (UCSD), La Jolla, California, USA.
- Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, California, USA.
ORCID-Profile: Ricardo da Silva Antunes, Alessandro Sette
Förderung
- NIH HHS
- NIAID NIH HHS
- National Institutes of Health
- Vetenskapsrådet
Zitieren
APA
Johansson, E., Lee, Y., Fajardo-Rosas, V., Abawi, A., Logandha Ramamoorthy Premlal, A., Frazier, A., Greenbaum, J. A., Vijayanand, P., da Silva Antunes, R., & Sette, A. (2026). Symptomatic SARS-CoV-2 breakthrough infections broaden the repertoire of Spike-reactive CD4 T cells. mBio. https://doi.org/10.1128/mbio.03549-25
Vancouver
Johansson E, Lee Y, Fajardo-Rosas V, Abawi A, Logandha Ramamoorthy Premlal A, Frazier A, et al. Symptomatic SARS-CoV-2 breakthrough infections broaden the repertoire of Spike-reactive CD4 T cells. mBio. 2026. doi:10.1128/mbio.03549-25
BibTeX
@article{Johansson2026,
author = {Johansson, Emil and Lee, Yeji and Fajardo-Rosas, Vicente and Abawi, Adam and Logandha Ramamoorthy Premlal, Ashmitaa and Frazier, April and Greenbaum, Jason A and Vijayanand, Pandurangan and da Silva Antunes, Ricardo and Sette, Alessandro},
title = {Symptomatic SARS-CoV-2 breakthrough infections broaden the repertoire of Spike-reactive CD4 T cells},
journal = {mBio},
year = {2026},
doi = {10.1128/mbio.03549-25}
}
EUVIMED